This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT00508287 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Bristol-Myers Squibb |
| Enrollment | 36 participants |
| Design | Interventional, Randomized, Crossover, Masking: Double |
| Conditions | Type 2 Diabetes |
| Interventions | BMS-686117; Byetta; Placebo |
| Start | Aug 2007 |
| Primary completion | Nov 2007 |
| Study completion | Nov 2007 |
| Results posted | Not yet |
| Registry last updated | Mar 16, 2009 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Safety: incidence of adverse events | from subject enrollment to study discharge |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.
More trials of ATX-304
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.